MAMehtap Aydin

Mehtap Aydin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehtap Aydin has a total of 254 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infection Prevention and Control in Türkiye: A Consensus Report from the 7th National Healthcare-Associated Infections Symposium

    by Tuğba Yanık-Yalçın, Elif Sargın-Altunok, Deniz Güven, Pakize Aygün, Mehtap Aydın, Özlem Azap, Gökhan Aygün, Halis Akalın, Önder Ergönül, Şiran Keske

    Antimicrobial resistance continues to threaten modern healthcare systems, increasing the importance of effective infection prevention and control (IPC). This study presents a thematic analysis of discussions from the 7th National Healthcare-Associated Infections Symposium (Ulusal Sağlık Bakımıyla İlişkili İnfeksiyonlar Simpozyumu, USBİS). Audio-recorded sessions involving IPC leaders and healthcare professionals across Türkiye were transcribed and analyzed to identify persistent barriers and potential solutions. Key barriers included reporting pressures affecting data reliability, behavioral and cultural barriers, limitations in education and workforce capacity, gaps in standardization, and difficulties implementing infection control committee decisions. Participants emphasized strengthening institutional IPC culture, improving leadership visibility, simplifying data systems, and prioritizing sustainable behavioral change strategies.

  • Correction to: The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023

    by Serap Şimşek-Yavuz, Selçuk Özger, Aysun Benli, Can Ateş, Mehtap Aydın, Gökhan Aygün, Alpay Azap, Özlem Kurt-Azap, Seniha Başaran, Neşe Demirtürk, et al.

    CORRECTION NOTE Two corrections have been made to the original version of this article, published on February 2, 2023: In Table 3, the information ‘DOX tablet 200 mg/day, single dose, oral +’ under the headings 1)Infective Endocarditis associated with Brucella spp. and 2) Neurobrucellosis has been corrected to: ‘DOX tablet 200 mg/day, 2 doses, oral +’. Corrected article: https://doi.org/10.36519/kd.2023.4576


  • Open Access

    Bone-Mineral Density in HIV-Positive Individuals Under 50 Years of Age: A Case-Control Study

    by Merve Çağlar-Özer, Selman Birkan Özer, Mehtap Aydın

    Objective: HIV infection may negatively impact bone microarchitecture, leading to reduced bone mineral density (BMD). This study compared the BMD of individuals under the age of 50 living with HIV to that of HIV-negative controls and evaluated the effect of antiretroviral therapy (ART) on BMD. Methods: In this cross-sectional case-control study conducted at the University of Health Sciences Ümraniye Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, medical records of 72 HIV-positive and 44 HIV-negative individuals aged 18–49 years were retrospectively reviewed between December 2021 and March 2022. Bone mineral density was measured using dual-energy X-ray absorptiometry (DEXA). Results: The prevalence of low BMD was 16.7% among HIV-positive individuals and 6.8% among HIV-negative controls. Lumbar spine T- and Z-scores were significantly lower in the HIV-positive group (ppp<0.05). No significant association was observed between BMD and CD4+ T cell count, viral load, vitamin D, or calcium levels. Conclusion: Individuals under 50 years of age living with HIV have lower BMD compared to HIV-negative individuals. These findings suggest that HIV infection may contribute to decreased BMD even in younger populations. Dual-energy X-ray absorptiometry screening should be considered in HIV-positive individuals under 50 years of age with additional risk factors for reduced BMD. Larger, multicenter studies are needed to confirm these results.

  • Open Access

    Impact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye

    by Elif Sargin-Altinok, Siran Keske, Ayse Batirel, Huseyin Bilgin, Ezgi Gulten, Sirin Menekse, Abdullah Gulbol, Petek Konya, Lutfiye Nilsun Altunal, Deniz Ozer, et al.

    Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from


  • Open Access

    Emerging West Nile virus infections in Türkiye

    by Özlem Alhan, Meliha Meriç Koç, Ayşe Batırel, Emel Yılmaz, Gülden Ersöz, Mehtap Aydın, Merve Üstüner Doğan, Hande Hazır Konya, Üner Kayabaş, Ferit Kuşçu, et al.

    Purpose: Türkiye experienced its largest West Nile virus (WNV) infection outbreak in 2024. We described the clinical and laboratory features of human cases with WNV infection collected from eleven tertiary hospitals in Türkiye in 2024. Methods: The clinical characteristics of the patients were gathered using a structured form in the retrospective study. According to the ECDC case definition of WNV infections, the patients were classified as ‘confirmed’ or ‘probable’ cases. The odds ratio (OR) and 95% confidence interval (CI) for possible mortality predictors in WNV infections were calculated using multivariate logistic regression analysis. p < 0.05 was considered statistically significant. Results: The mean age of the 51 patients was 63.3 ± 13.6 years, and 37 (72.5%) were male. Twenty-six cases (51%) were confirmed, and 49% were probable WNV infection. Forty-eight patients (94.1%) had WNV neuroinvasive disease: 24 (47%) were diagnosed with meningoencephalitis, 20 (39.2%) with encephalitis, one (2%) with meningitis, and seven (13.7%) with acute flaccid paralysis. Twenty patients (39.2%) had movement disorders (tremor, myoclonus, bradykinesia, or rigidity). The case fatality rate was 17.6%. In multivariate analysis, older age (OR: 1.09, CI: 1.03–1.19, p = 0.042) and secondary bacterial infection during hospitalization (OR: 10, CI: 1.55–64.95, p = 0.015) were associated with fatality. Conclusion: We highlighted the increasing number of cases and diagnostic challenges by describing the highest number of the patients with WNV infections in Türkiye. Raising awareness among healthcare professionals, facilitating access to diagnostic tests, and developing rapid, reliable, and easily applicable tests would enable early diagnosis and help improve outcomes.


  • Open Access

    Healthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis

    by Bahar Madran, Zeliha Genc, Siran Keske, Elif Sargin Altunok, Sirin Menekse, Ani Akpinar, Mehtap Aydin, Onder Ergonul

    Healthcare-associated infections (HAIs) are accepted as one of the most important challenges in hospital settings. They cause extended lengths of stay -at the hospital, threatening patient safety, increasing the rate of morbidity and mortality, raising the workforce of healthcare workers and accelerating antimicrobial resistance. According to the World Health Organization (WHO),


    • 27 March 2025
      • Vol. 7  (1) , 17-26
    Open Access

    Healthcare-Associated Infection Rates in Türkiye (2014-2023): A Systematic Review and Meta-Analysis

    by Bahar Madran, Zeliha Genç, Şiran Keske, Elif Sargın-Altunok, Şirin Menekşe, Anı Akpınar, Mehtap Aydın, Önder Ergönül

    This study aimed to describe the rate of Healthcare-Associated Infections (HAIs) in hospitals in the last decade (2014-2023), Türkiye. The study was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statements. The keywords were “Türkiye”, “healthcare-associated infections” (HAIs), “surgical site infections” (SSIs), “central line-catheter-associated bloodstream infections” (CLABSIs), “catheter-associated urinary tract infections” (CAUTI) and “ventilator-associated pneumonia” (VAP). We included all original articles reflecting the HAI rate of all adult patients in hospitals in Türkiye for at least one year of duration between January 01, 2014 and December 31, 2023. In total, 1171 reports, including the keywords, were retrieved, and duplications were removed. After filtering according to the title and abstract, eight original articles were selected. The quality of four reports published in peer-reviewed journals was rated as high, and the four as moderate. The rate of invasive device-associated HAIs in intensive care units (ICUs) was 4.19 (CLABSI: 1.97, CAUTI: 1.94, VAP: 6.49) and 1.88 in inpatient wards. No article was published that reflected the overall surgical site infection rate of a hospital. We detected that in the last 10 years (2014-2023) in Türkiye, invasive device-associated HAI rates were 1.88% in inpatient wards and 4.19% in ICU. More comprehensive studies should be conducted on HAI rates, frequently detected HAI agents, and resistance rates. Health centers should prioritize the issue, and intervention and prevention studies should be priority research topics.


  • Open Access

    A Systematic Review and Analysis of Brucella Endocarditis Cases

    by Seniha Başaran, Serap Şimşek-Yavuz, Mukime Elif Sarıcaoğlu, Mehtap Aydın, Gökhan Aygün, Alpay Azap, Özlem Azap, Aysun Benli, Neşe Demirtürk, Önder Ergönül, et al.

    Endocarditis is the most common cause of death from brucellosis. The information used to guide the management of cases with Brucella endocarditis has relied on case reports/series. Risk factors related to death and other adverse outcomes in patients with Brucella endocarditis were identified by an individual-patient data analysis of all reported Brucella endocarditis cases in the literature. The keywords “Bruce” and “endocard” were used to search articles published until July 2022 on PubMed and ULAKBIM databases. Case reports/series containing patients with endocarditis caused by Brucella spp., aged ≥17 years, and with data on antimicrobial or surgical treatment were included in the study. Epidemiological, clinical, laboratory, and treatment characteristics and outcomes of 273 cases from 86 eligible articles were recorded. It was found that male gender, a Wright serum tube agglutination (STA) titer of ≥1/1280 on admission, development of heart failure due to endocarditis were independent risk factors that increase mortality, while the usage of aminoglycoside and cardiac surgical intervention for endocarditis were factors reducing mortality. Including streptomycin or gentamicin in the treatment regimen may benefit patients with Brucella endocarditis. Valve surgery could be life-saving in patients with Brucella endocarditis. An STA titer of ≥1/1280, which probably reflects long-term and advanced disease, may be used as a marker for increased mortality. However, additional and more reliable studies are needed to define the most appropriate management approach in diagnosing and treating cases with Brucella endocarditis due to the low quality of the current evidence.


  • Open Access

    Use of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19

    by Kadir Gorkem Guclu, Ceyda Geyiktepe-Guclu, Osman Faruk Bayramlar, Gulsah Tuncer, Mehtap Aydin

    The aim of this study was to compare the clinical effects of the addition of anakinra to high-dose steroid therapy in COVID-19 patients with macrophage activation syndrome.


  • Open Access

    Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

    by Ihsan Ates, Ayse Batirel, Mehtap Aydin, Fatma Yilmaz Karadag, Abdulsamet Erden, Orhan Kucuksahin, Berkan Armagan, Serdar Can Guven, Ozlem Karakas, Selim Gokdemir, et al.

    The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day 84) immunogenicity results of the double-blind, randomized, controlled, phase II Hybrid COV-RAPEL TR Study (NCT04979949), in which the TURKOVAC or CoronaVac vaccines were used as a booster after the second dose of primary vaccination with CoronaVac. A total of 190 participants from the Hybrid COV-RAPEL TR Study, who had both Day 28 and Day 84 immunogenicity results, were included. The immunogenicity on Day 84, regarding the neutralizing antibody positivity (Wuhan and Delta variants) and anti-spike immunoglobulin (Ig) G (IgG) antibody positivity, was compared between TURKOVAC and CoronaVac vaccine arms according to sex and age groups. Overall, antibody positivity showed a slight decrease on Day 84 vs. Day 28, but was not different between TURKOVAC and CoronaVac arms either for sexes or for age groups. However, TURKOVAC produced better antibody response against the Delta variant than CoronaVac, while CoronaVac was superior over TURKOVAC regarding neutralizing antibody positivity in the 50–60 years age group, regardless of the variant. A single booster dose, after the completion of the primary vaccination, increases antibody positivity on Day 28 which persists until Day 84 with a slight decrease. However, an additional booster dose may be required thereafter, since the decrease in antibody titer may be faster over time.